Prime Therapeutics is committed to simplifying the patient journey for those with complex conditions through its industry-leading HighTouchRx product

Findings also show improved persistence with high-potency, obesity-approved GLP-1 products

Event features discussions about health care industry trends, best practices and innovations

Formulary design recommendations help create competition to drive savings, provide optionality to meet unique client needs.

Leading GLP-1 persistence, adherence and clinical outcomes research helps inform health plans and members

Studies include Prime’s GLP-1 obesity research, the impact of social determinants of health and more.

Urick, senior principal health outcomes researcher, shares more about his Spotlight Session at the Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting

Prime Therapeutics clinical experts shared insights on the specialty drug pipeline at recent industry event

A look at the specialty landscape and how Prime delivers value to employers

Stories, perspectives and news coverage of Prime Therapeutics/Magellan Rx from AMCP 2024